Loading...
•
Dec 31, 2025
•/
BioNTech SE Q4 2025 Earnings Report
BioNTech reported lower quarterly revenue and a net loss as COVID-19 vaccine demand declined while the company continued investing heavily in oncology research and development.
Key Takeaways
BioNTech posted declining revenue and a net loss in Q4 2025 due to reduced COVID-19 vaccine demand, while maintaining significant R&D investment to advance its oncology pipeline.
Revenue declined year-over-year to 907400000 due to reduced COVID-19 vaccine demand.
Net loss reached -305000000 compared to a profit in the prior year period.
R&D spending remained substantial at 505400000 as the company advanced oncology programs.
BioNTech maintained a very strong liquidity position with large cash and securities holdings.
Forward Guidance
BioNTech expects lower revenue in 2026 due to declining COVID-19 vaccine demand while continuing large investments in oncology R&D programs.
Positive Outlook
- Expected 2026 revenue between 2000000000 and 2300000000.
- Strong financial position supports continued R&D investment.
- Multiple late-stage oncology trial readouts expected in 2026.
- Strategic collaboration revenues expected to remain stable.
- Pipeline progress across immunotherapies and antibody-drug conjugates.
Challenges Ahead
- Expected decline in COVID-19 vaccine revenue in the U.S. and Europe.
- High R&D spending projected between 2200000000 and 2500000000.
- SG&A expenses expected between 700000000 and 800000000.
- Revenue visibility tied to evolving vaccine market demand.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...